Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X about a recent article she and her colleagues co-authored, adding:
“Hot off the press. It’s not just about PDL1 and PD1. High PDL2 RNA correlates with longer survival after anti-PD1 IO.”
Title: PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis
Authors: Anannya Patwari, Daisuke Nishizaki, Taylor Jensen, Paul DePietro, Sarabjot Pabla, Shumei Kato, Razelle Kurzrock
Read the Full Article on JCO Oncology Advances
More posts featuring Immunotherapy.
